Balance Sheet
Includes Current Assets, Liabilities and Stockholder's Equity
Quarter Ended Jun 30, 2023
Revenue for the three and six months ended June 30, 2023, was $5.1 million and $52.7 million, respectively, compared to $5.5 million and $9.1 million for the same periods in 2022.
As of June 30, 2023, Adaptimmune had cash and cash equivalents of $77.0 million and Total Liquidity1 of $204.7 million, compared to $108.0 million and $204.6 million, respectively, as of December 31, 2022.
1Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.
For Fiscal Year Ending Dec 31, 2022
For complete information regarding our financials, see our periodic filings